Published in Clin Immunol on October 01, 1999
Passive Immunity Trial of Nashville II for COVID-19 (PassItOnII) | NCT04362176
Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev (2000) 2.38
Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology (2011) 1.53
Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis (2002) 1.51
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun (2003) 1.23
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis. Infect Immun (2000) 0.88
Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis. Antimicrob Agents Chemother (2002) 0.85
Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PLoS One (2010) 0.84
Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development. Hum Reprod (2008) 0.82
Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery. Methods Mol Biol (2009) 0.82
Vaccine for human contraception targeting sperm Izumo protein and YLP12 dodecamer peptide. Protein Sci (2014) 0.80
Characterization of an intestinal epithelial cell receptor recognized by the Cryptosporidium parvum sporozoite ligand CSL. Infect Immun (2001) 0.80
Development of genetically engineered human sperm immunocontraceptives. J Reprod Immunol (2009) 0.78
Production of recombinant antibodies using bacteriophages. Eur J Microbiol Immunol (Bp) (2014) 0.77
Status of contraceptive vaccines. Am J Reprod Immunol (2009) 0.76
Active immunity induced by passive IgG post-exposure protection against ricin. Toxins (Basel) (2014) 0.75
Antibody Engineering for Pursuing a Healthier Future. Front Microbiol (2017) 0.75
Complexation Hydrogels as Oral Delivery Vehicles of Therapeutic Antibodies: An in Vitro and ex Vivo Evaluation of Antibody Stability and Bioactivity. Ind Eng Chem Res (2015) 0.75
Biological activity of a mouse-human chimeric immunoglobulin G2 antibody to Cryptococcus neoformans polysaccharide. Clin Diagn Lab Immunol (2002) 0.75